BTG3 and rheumatoid arthritis: There is also evidence suggesting that the relatively low frequency (<5%) of these antibodies, particularly when they are the sole ANA pattern in serum, in AARD makes them potentially useful biomarkers to rule out the presence of systemic autoimmune disease, although they may not help in ruling out RA [4, 14–17].